Core Viewpoint - The establishment of the "National Key Laboratory of Precious Metal Functional Materials" led by Yunnan Precious Metals New Materials Holding Group Co., Ltd. aims to focus on technological breakthroughs in the field of precious metal materials, supporting the upgrade of China's new materials industry and ensuring resource security and high-end equipment manufacturing [1][2]. Group 1: Laboratory Objectives and Focus Areas - The laboratory will focus on three main directions: "special functional materials of precious metals," "catalytic functional materials of precious metals," and "recycling of secondary resources of precious metals," aiming to achieve breakthroughs in key core technologies [1]. - The laboratory seeks to establish a technology system with independent intellectual property rights and create a solid patent protection moat in the field of precious metals, enhancing technological competitiveness and industrial security [1]. Group 2: Collaboration and Innovation - Experts and academicians discussed the construction plan of the national key laboratory, including its positioning, research directions, and mechanisms for collaboration between academia and industry [2]. - Suggestions were made to strengthen demand-oriented basic research and enhance collaborative innovation with universities and enterprises to improve China's independent innovation capabilities in precious metal materials [2].

中证报中证网讯（记者 乔翔）4月25日晚，安路科技发布2024年年报。2024年，安路科技实现营业 收入6.52亿元，净利润为-2.05亿元。 虽然短期受行业波动影响，但公司通过技术创新与生态扩张，实现业务韧性发展——全年产品销量 同比增长46.14%。 2024年，安路科技持续深化现有市场经营，积极推进新兴市场布局。产品在多个应用场景实现重要 突破，客户群体持续扩容，应用领域进一步拓展，在工业、音视广播、数据中心、消费电子等传统领域 保持稳健增长，并成功开拓了机器视觉、智能制造、智慧医疗、高端显示等应用领域；汽车FPGA生态 进一步完善，车规芯片在电子后视镜、激光雷达等场景批量应用，带动销售收入增长；PH1P/DR1等高 性能系列产品在电力系统、新能源、机器人等高潜力领域实现客户导入和批量应用。同时，公司积极拓 展海外市场，加强与国际合作伙伴的战略合作，进一步完善全球销售网络体系，推动业务的国际化发 展。 2024年，安路科技研发费用总额达3.64亿元，为未来的价值释放奠定了坚实基础。截至2024年年 末，研发团队规模扩充至452人，累计申请知识产权440项，其中发明专利246项；累计获得知识产权授 权28 ...

中证报中证网讯（记者 罗京）近期，为帮助辖区上市公司积极应对外部环境变化的影响，助力上 市公司高质量发展，厦门证监局联合厦门市委金融办认真落实常态化走访上市公司机制，走访了金达 威、松霖科技、盈趣科技、建霖家居等多家上市公司，了解企业业务总体情况，倾听困难诉求，协调解 决问题，引导公司及时调整战略布局，持续加大研发创新力度，运用好增持回购、分红等工具加强市值 管理，及时回应、披露外部影响，稳定投资者信心。 2024年以来，厦门证监局密切配合地方政府成立推动上市公司高质量发展工作专班，建立高规格的 走访上市公司工作机制，联合地方政府和交易所走访调研上市公司80家次，其中配合厦门市领导走访辖 区超七成上市公司、市区两级领导实现走访上市公司全覆盖，协调推动解决上市公司各类诉求93项。 厦门证监局在常态化走访的基础上，持续跟踪诉求解决，密切配合厦门市政府建立多层次上市公司 诉求常态化解决机制。一是厦门市政府指定市委金融办牵头定期收集辖区上市公司生产经营中遇到的问 题和困难，逐家公司、逐个事项形成工作台账，明确具体责任单位，由厦门市领导召集政企沟通协调会 议并进行督办，压茬推进解决企业诉求，实行"一对一"销号管理。二是 ...

Core Viewpoint - 威胜信息 reported a strong performance in Q1 2025, with significant growth in revenue and net profit, driven by robust order intake and technological innovation [1][2]. Financial Performance - The company achieved a revenue of 555 million yuan, representing a year-on-year increase of 24% [1]. - The net profit attributable to shareholders reached 139 million yuan, up 25.3% year-on-year [1]. - Operating cash flow was 79.86 million yuan, reflecting a growth of 38.3% compared to the previous year [1]. - New contracts signed in Q1 amounted to 777 million yuan, a 30.4% increase year-on-year, with total backlog reaching 4.108 billion yuan [1]. Technological Innovation - 威胜信息 has invested a total of 667 million yuan in R&D over the past three years, averaging 9.6% of revenue [1]. - The company has developed a core competitive advantage in "IoT + chips + AI," providing comprehensive solutions from data collection to analysis [1]. - The self-developed communication chip supports AMI communication solutions for over 70% of countries globally, enhancing the company's international technological capabilities [1][2]. Strategic Initiatives - The company integrates AI technologies into new power system construction, achieving breakthroughs in predictive maintenance and operational efficiency [2]. - In the smart city sector, 威胜信息 has developed AI edge computing gateways and smart security management platforms, enhancing capabilities in edge computing and security [2]. - The company is focused on international expansion, particularly in Belt and Road Initiative countries, with a strategy of "trade + empowerment + integration" [2][3]. Shareholder Returns - 威胜信息 has prioritized shareholder returns, distributing a cash dividend of 5.2 yuan per 10 shares, totaling 250 million yuan [3]. - Cumulatively, the company has distributed 958 million yuan in dividends and repurchased approximately 200 million yuan in shares since its listing, totaling 1.16 billion yuan in returns [3]. - The company commits to maintaining a baseline dividend payout ratio of 40% over the next five years, promoting a stable return mechanism [3].

中证报中证网讯（王珞）4月24日晚间，慧博云通发布2024年年度报告，慧实现营业总收入17.4亿 元，同比增长28.30%；扣除实施股权激励的股份支付后的归属于上市公司股东扣非净利润7024万元， 同比增长6.68%。 慧博云通自2022年上市后连续三年分红，2024年度公司拟向全体股东每10股派发现金红利0.8元 （含税）。 慧博云通主营业务包括软件技术服务、专业技术服务、产品与解决方案三大类。报告期内，公司软 件技术服务业务实现营业收入10.74亿元，同比增长16.70%；专业技术服务业务实现营业收入4.97亿 元，同比增长58.69%；产品与解决方案业务实现营业收入1.478亿元，同比增长32.39%。 慧博云通推进实施2+3发展战略，以TMT和金融两大行业为核心阵地，持续强化人工智能、大数据 和金融科技三大技术支柱，系统构建差异化竞争优势。公司为全球TMT、金融科技、汽车、能源等行 业的客户提供涵盖软件技术服务、专业技术服务、产品与解决方案全生命周期的信息技术服务。在长期 发展过程中，公司已建立起优质的客户网络，为客户提供从咨询规划到运维运营的全生命周期IT服务， 助力众多客户实现数字化升级与智能化转 ...

中证报中证网讯(王珞)4月25日，2025中国人形机器人生态大会暨智能机器人与未来科技展在上海开 幕。派斯林（600215）在活动现场推出了飞机装配生产环节智能机器人应用解决方案。 派斯林相关负责人表示，公司未来将持续深化智能机器人产业战略布局，重点突破人形机器人、仿生机 器人规模化应用；依托工业场景优势，构建多维度技术矩阵，加强真实场景数据采集，攻坚AI大模型 算法与视觉识别系统研发。同时，以汽车制造、智能仓储、飞机装配场景为锚点，通过技术赋能、生态 共建加速智能机器人在高端制造领域产业化落地。 作为深耕工业自动化领域的国际化企业，派斯林在汽车制造、智能仓储及一般工业自动化产线场景应用 方面积累了丰富的实践经验和核心技术储备。公司重点聚焦机器人自动化与智能制造，坚持自主创新， 为客户提供工业自动化智能制造整体解决方案，业务广泛应用于汽车制造、新能源、工程机械、智能仓 储、装配式建筑、数字工厂等领域。 基于汽车装配领域的先发优势以及未来市场需求空间，派斯林与上海交通大学合作研发了适用于大型装 备制造装配的六足仿生机器人。该系列机器人可负重80kg，实现6个自由度，未来有望在飞机总装自动 化等大型装备领域开展应 ...

报告期内，公司积极探索AI技术与生物制造的深度融合，成立AI技术开发及应用实验室，稳步推进AI 技术在酶蛋白功能特性优化、酶蛋白质高效表达的代谢网络调控及菌种智能发酵优化等领域的探索与实 践。 在完善动物大健康系统方面，蔚蓝生物构建产业+服务的综合赋能平台，提供涵盖动物营养、健康养 殖、动物疫病的系统化解决方案。特别是公司VLAND-PCP定制酶方案(基于饲料酶应用大数据系统的精 准定制平台)已积累上百种饲料原料用酶数据库并持续更新，已获得众多大客户的认可。 中证报中证网讯(记者张鹏飞)蔚蓝生物（603739）4月25日晚间发布2024年度报告。报告显示，公司全 年实现营业收入13.21亿元，同比增长10.16%；实现归属于上市公司股东的净利润6263.75万元，同比下 降22.39%。公司全年研发投入达1.18亿元，占营收比例8.95%，通过技术创新与全球化布局，公司夯实 核心竞争力，推动长期可持续发展。 酶制剂被誉为工业生物技术领域的"芯片"，其中表达系统的构建是微生物生产菌株开发的核心，也是产 品从实验室迈向大规模生产的关键。目前，蔚蓝生物已构建里氏木霉、毕赤酵母、黑曲霉、芽孢杆菌四 大高效蛋白质表达系 ...

Group 1 - The company reported a revenue of 5.085 billion yuan for 2024, an increase of 11.10% year-on-year, while the net profit attributable to shareholders decreased by 75.01% to 13.6075 million yuan [1] - In Q1 2025, the company achieved a revenue of 1.117 billion yuan, a slight decline of 0.83% year-on-year, but the net profit attributable to shareholders surged by 390.50% to 5.67 million yuan [1] - The metal products segment generated a revenue of 3.663 billion yuan, with a gross margin of 11.71%, reflecting a year-on-year increase of 12.25% and 3.03% respectively [1] Group 2 - The chemical segment experienced a revenue of 1.161 billion yuan, a significant increase of 37.56% year-on-year, despite facing market pressures due to supply-demand imbalances [2] - The production of silicone and related products reached 90,500 tons, with sales of 86,400 tons, marking growth of 60.41% and 46.80% year-on-year respectively [2] - The company invested 171 million yuan in R&D for 2024, an increase of 12.03%, and is recognized as a high-tech enterprise in Henan province [2] Group 3 - For 2025, the company aims to achieve a strategic goal of "double hundred billion" in terms of output value and market value, focusing on the dual development of metal and chemical products [3] - The company plans to enhance its overseas market expansion and diversify its business through precise market positioning and scientific strategy layout [3] - The operational strategy emphasizes quality, cost, and market as the three main business subjects to drive high-quality development [3]

Core Viewpoint - The company reported significant financial results for 2024 and Q1 2025, alongside major advancements in its innovative drug development pipeline [1][2]. Financial Performance - In 2024, the company achieved a revenue of 1.45 billion yuan, with a net profit attributable to shareholders of -540 million yuan [1]. - For Q1 2025, the company reported a revenue of 377 million yuan and a net profit of 56.59 million yuan [1]. Research and Development - The company invested 325 million yuan in R&D in 2024, accounting for 22.40% of its revenue, with Q1 2025 R&D investment reaching 74.43 million yuan, an increase of 18.71% year-on-year [2]. - As of Q1 2025, the company has 71 projects under research, including 15 innovative drug projects, with 34 projects/products in the filing or approval stage [2]. Product Development and Innovation - The innovative drug AR882 received Fast Track Designation (FTD) from the FDA for treating visible tophi in clinical gout patients, marking a significant milestone [1]. - The global pivotal Phase III REDUCE2 trial for AR882 completed patient enrollment, advancing the drug's development towards commercialization [1]. Manufacturing and Production Capabilities - The company has established an integrated business model encompassing R&D, production, and sales, with capabilities in the entire pharmaceutical industry chain [2]. - The company has built two innovative production bases, including the Yipin Hong Lianrui Biopharmaceutical Intelligent Manufacturing Base, enhancing its production capacity for generic and innovative raw materials [2]. Future Plans - In 2025, the company aims to accelerate clinical trials for key projects like AR882 and APH01727, while enhancing its innovation team and attracting top talent in drug development [3]. - The company plans to optimize its R&D management capabilities and strengthen the layout of its product pipeline and patent protection efforts [3].

在工业与卫星方向，当虹科技提供视频汇聚、视频感知压缩、视频分析、AI模型等产品及服务，如卫 星通信、轨道交通、煤炭、远洋船舶等行业客户。当虹端侧智能盒完美兼顾了"视频超级压缩+视觉AI 识别"双重业务需求，效果显著，召回率和准确率均超过98%。 在智能网联汽车方向，公司深度拓展车载智能娱乐座舱方向，充分发挥视频技术优势、视频创新优势、 视频生态优势、跨界合作优势，聚焦娱乐化、智能化、交互多样化，打造面向未来的All-in-One沉浸式 视听座舱体验。此外，当虹科技基于公司发布的"DeepSeek+BlackEye"多模态大模型，开展当虹座舱端 侧大模型落地，为智能座舱及智能驾驶带来了全新的智能和互动体验提升。 中证报中证网讯(记者王辉)科创板公司当虹科技近日发布2024年报。年报显示，2024年公司实现营业收 入3.07亿元；归属于母公司股东的净利润为-1.02亿元，较上年同期减少亏损额3599.55万元。毛利率达 41%，同比提升5.74个百分点，实现毛利率连续两年提升。与此同时，年报相关信息进一步显示，智能 网联汽车、工业与卫星业务等领域成为公司2024年新增长点 具体来看，工业与卫星业务、智能网联汽车业 ...